Fig. 3
From: Novel target and treatment agents for natural killer/T-cell lymphoma
Novel agents targeting signaling pathways, including JAK/STAT, NF-κB, PDGFR, VEGF/VEGFR, PI3K/Akt/ mTOR, XPO1 and AURKA. PDGFR: platelet-derived growth factor receptor, VEGF: vascular endothelial growth factor, PI3K/Akt: phosphatidylinositol 3-kinase/protein kinase B, mTOR: mammalian target of rapamycin, XPO1: exportin-1, AURKA: Aurora kinase A